Related Experiment Videos
Dynamics of beta-adrenoceptor blockade with cetamolol
British Journal of Clinical Pharmacology
|April 1, 1985
Summary
Cetamolol, a beta-adrenoceptor blocker, effectively reduces exercise-induced heart rate and blood pressure in healthy individuals. Its beta-1 selective blockade is dose-dependent and lasts up to 24 hours, demonstrating clinical significance.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Clinical Trials
Background:
- Cetamolol is a novel beta-adrenoceptor antagonist.
- Preclinical studies indicated moderate beta-1 selectivity and partial agonist activity.
Purpose of the Study:
- To evaluate the beta-1 adrenoceptor blockade of cetamolol in healthy volunteers.
- To assess the dose-response relationship and duration of action of cetamolol.
Main Methods:
- Healthy volunteers received single oral doses of cetamolol (10, 25, 50 mg).
- Beta-1 adrenoceptor blockade was assessed by measuring reductions in exercise-induced tachycardia, systolic blood pressure, and double product at 2, 8, and 24 hours.
- A crossover study with 0, 10, and 25 mg doses confirmed findings.
Main Results:
- A significant, linear relationship was observed between log serum cetamolol levels and beta-1 adrenoceptor blockade.
- The blockade effect was maximal at 2 hours post-dose.
- Clinically significant blockade persisted for up to 24 hours.
Conclusions:
- Cetamolol demonstrates dose-dependent beta-1 adrenoceptor blockade in humans.
- The drug exhibits a prolonged duration of action, with significant effects lasting 24 hours.
- Cetamolol's pharmacokinetic and pharmacodynamic profile supports its potential as a cardiovascular therapeutic agent.